CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen has raised $6.8M in total funding. The most recent round was Grant. The last funding was announced in December 2023.
CaroGen's investors include Connecticut Innovations, U.S. Department of War, National Institutes of Health.
CaroGen is headquartered in Hamden, United States.
CaroGen develops vaccine candidates targeting hepatitis B and C, and other viral agents.
CaroGen is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"CaroGen — Funding & Investors." VCBacked, December 12, 2023, https://www.vcbacked.co/company/carogen. Accessed July 20, 2026.
VCBacked. (2023). CaroGen — Funding & Investors. Retrieved July 20, 2026, from https://www.vcbacked.co/company/carogen
{{cite web |title=CaroGen — Funding & Investors |url=https://www.vcbacked.co/company/carogen |website=VCBacked |access-date=July 20, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated